The U.S. biologics and biosimilars markets evolved rapidly in 2018. On January 17, life sciences attorneys John Adkisson, Tasha Francis, and Jenny Shmuel reviewed the U.S. market for biosimilar products and provide insights into:
• Which biosimilars have been approved and launched
• Recent regulatory and legislative actions impacting the biosimilars market
• Select court cases and See more +
The U.S. biologics and biosimilars markets evolved rapidly in 2018. On January 17, life sciences attorneys John Adkisson, Tasha Francis, and Jenny Shmuel reviewed the U.S. market for biosimilar products and provide insights into:
• Which biosimilars have been approved and launched
• Recent regulatory and legislative actions impacting the biosimilars market
• Select court cases and settlements
• Recent trends in IPR filings in the biosimilars space
• What to look forward to in 2019
See less -
